指南与共识治疗药物监测与药物基因组学药物不良反应与药物警戒

CPIC指南:CYP2C19基因型与质子泵抑制剂给药剂量

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
指南 / 共识 · Clin Pharmacol Ther · 2020-09-20

本指南由临床药物遗传学实施联盟(CPIC)制定,基于文献证据汇总CYP2C19基因型与质子泵抑制剂(PPI)暴露、疗效及不良反应的关联,并提供基于CYP2C19基因型的PPI处方治疗推荐。指南指出,利用CYP2C19基因型数据可识别血浆暴露较低的患者并给予较高剂量以提高疗效,或识别长期治疗中血浆暴露较高的患者并降低剂量以减少长期PPI使用相关的毒性风险。

要点

  • CYP2C19基因型与PPI血浆暴露、疗效及不良反应相关。
  • 基因型预测低暴露者可考虑较高剂量以提高疗效。
  • 长期治疗中基因型预测高暴露者可考虑降低剂量以减少毒性。

核心结论

  • CYP2C19基因型数据可用于指导PPI治疗,识别低暴露患者给予较高剂量以提高疗效,或识别高暴露患者降低剂量以减少长期使用相关毒性风险。

研究设计与样本

  • 临床药物遗传学实施联盟(CPIC)制定的指南,基于文献证据汇总并提供基于CYP2C19基因型的PPI处方治疗推荐。

主要发现

  • 大多数PPI主要经细胞色素P450 2C19(CYP2C19)代谢为无活性代谢物。
  • CYP2C19基因型与PPI暴露、疗效及不良反应相关。

临床怎么用

  • 利用CYP2C19基因型数据识别血浆暴露较低的患者,给予较高剂量以提高疗效。
  • 识别长期治疗中基因型预测血浆暴露较高的患者,降低剂量以减少长期PPI使用相关的毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and prevention of many conditions, including gastroesophageal reflux disease, gastric and duodenal ulcers, erosive esophagitis, Helicobacter pylori infection, and pathological hypersecretory conditions. Most PPIs are metabolized primarily by cytochrome P450 2C19 (CYP2C19) into inactive metabolites, and CYP2C19 genotype has been linked to PPI exposure, efficacy, and adverse effects. We summarize the evidence from the literature and provide therapeutic recommendations for PPI prescribing based on CYP2C19 genotype (updates at www.cpicpgx.org). The potential benefits of using CYP2C19 genotype data to guide PPI therapy include (i) identifying patients with genotypes predictive of lower plasma exposure and prescribing them a higher dose that will increase the likelihood of efficacy, and (ii) identifying patients on chronic therapy with genotypes predictive of higher plasma exposure and prescribing them a decreased dose to minimize the risk of toxicity that is associated with long-term PPI use, particularly at higher plasma concentrations.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2020. PMID: 32770672. doi:10.1002/cpt.2015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。